IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd MISSELWITZ

Examiner: JONES, Dameron Levest

Serial No.: 10/616,511

Group Art Unit: 1618

Filed: July 10, 2003

Title: USE OF PERFLUOROALKYL-CONTAINING METAL COMPLEXES AS CONTRAST MEDIA IN MR-IMAGING FOR VISUALIZATION OF INTRAVASCULAR THROMBI

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to the restriction requirement dated August 25, 2005, applicants elect with traverse group 19, and as a single species elect the compound denoted MK13 in table I on page 28 of the specification.

MK13 has the following substituents when looking at claim 30:

- compound of formula Ic
- R is a monosacharide radical bonded by the 1-OH position (mannose)
- R^F is a perfluorinated, straight chain carbon chain with the formula $-C_8F_{16}F$ (n=8, E=F)
- K is a metal complex of formula IIc
- R^1 is a metal equivalent of atomic number 64
- R^2 is C_1-alkyl (methyl)
- R^3 is hydrogen
- U is $-(CH_2)_1-$
- G is radical (a1)
- L^1, m^1 and p^1 are 1
- Y is $\delta-(CH_2)_1-CO-\beta$

- Z is



and the structure of MK13 is:



The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908
Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1911

September 15, 2005

K:\Sch\1911\Reply Sep 05.doc